122 related articles for article (PubMed ID: 12182847)
21. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
Ducrot P; Legraverend M; Grierson DS
J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
[TBL] [Abstract][Full Text] [Related]
22. Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine.
Schulze-Gahmen U; Brandsen J; Jones HD; Morgan DO; Meijer L; Vesely J; Kim SH
Proteins; 1995 Aug; 22(4):378-91. PubMed ID: 7479711
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of potent CDK1 inhibitors derived from olomoucine.
Furet P; Zimmermann J; Capraro HG; Meyer T; Imbach P
J Comput Aided Mol Des; 2000 Jul; 14(5):403-9. PubMed ID: 10896313
[TBL] [Abstract][Full Text] [Related]
24. [The characterization of human cdc2 kinase and CDK2].
Yasuda H; Kamijo M; Ohba Y
Yakugaku Zasshi; 1993 Dec; 113(12):829-46. PubMed ID: 8301538
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator.
Bessa M; Saville MK; Watson RJ
Oncogene; 2001 Jun; 20(26):3376-86. PubMed ID: 11423988
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
27. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.
Mendoza N; Fong S; Marsters J; Koeppen H; Schwall R; Wickramasinghe D
Cancer Res; 2003 Mar; 63(5):1020-4. PubMed ID: 12615717
[TBL] [Abstract][Full Text] [Related]
28. Structures of staurosporine bound to CDK2 and cAPK--new tools for structure-based design of protein kinase inhibitors.
Toledo LM; Lydon NB
Structure; 1997 Dec; 5(12):1551-6. PubMed ID: 9438871
[TBL] [Abstract][Full Text] [Related]
29. Crystal structure of a gamma-herpesvirus cyclin-cdk complex.
Card GL; Knowles P; Laman H; Jones N; McDonald NQ
EMBO J; 2000 Jun; 19(12):2877-88. PubMed ID: 10856233
[TBL] [Abstract][Full Text] [Related]
30. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
[TBL] [Abstract][Full Text] [Related]
31. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
Sims PA; Wong CF; McCammon JA
J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
[TBL] [Abstract][Full Text] [Related]
32. Kinetic mechanism of activation of the Cdk2/cyclin A complex. Key role of the C-lobe of the Cdk.
Morris MC; Gondeau C; Tainer JA; Divita G
J Biol Chem; 2002 Jun; 277(26):23847-53. PubMed ID: 11959850
[TBL] [Abstract][Full Text] [Related]
33. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
[TBL] [Abstract][Full Text] [Related]
34. The cell cycle inhibitor p21CIP is phosphorylated by cyclin A-CDK2 complexes.
Jaumot M; Estañol JM; Casanovas O; Graña X; Agell N; Bachs O
Biochem Biophys Res Commun; 1997 Dec; 241(2):434-8. PubMed ID: 9425288
[TBL] [Abstract][Full Text] [Related]
35. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
Gibson AE; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Whitfield HJ
J Med Chem; 2002 Aug; 45(16):3381-93. PubMed ID: 12139449
[TBL] [Abstract][Full Text] [Related]
36. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.
Schulman BA; Lindstrom DL; Harlow E
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10453-8. PubMed ID: 9724724
[TBL] [Abstract][Full Text] [Related]
37. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine.
Filgueira de Azevedo W; Gaspar RT; Canduri F; Camera JC; Freitas da Silveira NJ
Biochem Biophys Res Commun; 2002 Oct; 297(5):1154-8. PubMed ID: 12372407
[TBL] [Abstract][Full Text] [Related]
38. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.
Kim KS; Kimball SD; Misra RN; Rawlins DB; Hunt JT; Xiao HY; Lu S; Qian L; Han WC; Shan W; Mitt T; Cai ZW; Poss MA; Zhu H; Sack JS; Tokarski JS; Chang CY; Pavletich N; Kamath A; Humphreys WG; Marathe P; Bursuker I; Kellar KA; Roongta U; Batorsky R; Mulheron JG; Bol D; Fairchild CR; Lee FY; Webster KR
J Med Chem; 2002 Aug; 45(18):3905-27. PubMed ID: 12190313
[TBL] [Abstract][Full Text] [Related]
39. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717.
Dreyer MK; Borcherding DR; Dumont JA; Peet NP; Tsay JT; Wright PS; Bitonti AJ; Shen J; Kim SH
J Med Chem; 2001 Feb; 44(4):524-30. PubMed ID: 11170642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
